Linked Life Data

17307161

Source:http://linkedlifedata.com/resource/pubmed/id/17307161

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17307161rdf:typepubmed:Citationlld:pubmed
pubmed-article:17307161lifeskim:mentionsumls-concept:C0004096lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0599779lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0014457lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0079189lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0439799lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C0205087lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C1456443lld:lifeskim
pubmed-article:17307161lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:17307161pubmed:issue2-3lld:pubmed
pubmed-article:17307161pubmed:dateCreated2007-3-9lld:pubmed
pubmed-article:17307161pubmed:abstractTextT cells play a regulatory role in the pathogenesis of various immune and allergic diseases, including human asthma. Recently, it was reported that a pyrazole derivative, YM-58483 (BTP2), potently inhibits Ca(2+) release-activated Ca(2+) (CRAC) channels and interleukin (IL)-2 production in T cells. We investigated the effects of YM-58483 on T helper type 2 (Th2) cytokine production in vitro and antigen-induced airway asthmatic responses in vivo. YM-58483 inhibited IL-4 and IL-5 production in a conalbumine-stimulated murine Th2 T cell clone (D10.G4.1), and IL-5 production in phytohemagglutinin-stimulated human whole blood cells with IC(50) values comparable to those reported for its CRAC channel inhibition (around 100 nM). YM-58483 inhibited antigen-induced eosinophil infiltration into airways, and decreased IL-4 and cysteinyl-leukotrienes content in inflammatory airways induced in actively sensitized Brown Norway rats. Furthermore, orally administered YM-58483 prevented antigen-induced late phase asthmatic bronchoconstriction and eosinophil infiltration in actively sensitized guinea pigs. These data suggest that the inhibition of Ca(2+) influx through CRAC channel leads to the prevention of antigen-induced airway inflammation, probably via the inhibition of Th2 cytokine production and inflammatory mediators release. YM-58483 may therefore be useful for treating airway inflammation in bronchial asthma.lld:pubmed
pubmed-article:17307161pubmed:languageenglld:pubmed
pubmed-article:17307161pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:citationSubsetIMlld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17307161pubmed:statusMEDLINElld:pubmed
pubmed-article:17307161pubmed:monthAprlld:pubmed
pubmed-article:17307161pubmed:issn0014-2999lld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:IshikawaJunJlld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:YamadaToshimi...lld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:HondaKazuoKlld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:MorokataTatsu...lld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:OhgaKeikoKlld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:YoshinoTaijiTlld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:TakezawaRyuic...lld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:MorioHirokiHlld:pubmed
pubmed-article:17307161pubmed:authorpubmed-author:OkadaYouheiYlld:pubmed
pubmed-article:17307161pubmed:issnTypePrintlld:pubmed
pubmed-article:17307161pubmed:day10lld:pubmed
pubmed-article:17307161pubmed:volume560lld:pubmed
pubmed-article:17307161pubmed:ownerNLMlld:pubmed
pubmed-article:17307161pubmed:authorsCompleteYlld:pubmed
pubmed-article:17307161pubmed:pagination225-33lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:meshHeadingpubmed-meshheading:17307161...lld:pubmed
pubmed-article:17307161pubmed:year2007lld:pubmed
pubmed-article:17307161pubmed:articleTitleYM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models.lld:pubmed
pubmed-article:17307161pubmed:affiliationPharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. taiji.yoshino@jp.astellas.comlld:pubmed
pubmed-article:17307161pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17307161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17307161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17307161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17307161lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17307161lld:pubmed